Coherus BioSciences saw the highest growth of 1.99% in patent filings and no patents were granted in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Coherus BioSciences’s patent filings and grants. Buy the databook here.
Coherus BioSciences has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 100% of filings. The United States(US) patent Office are among the top ten patent offices where Coherus BioSciences is filings its patents..
Regeneron Pharmaceuticals could be the strongest competitor for Coherus BioSciences
Patents related to nanomedicine and rare diseases lead Coherus BioSciences's portfolio
Coherus BioSciences has the highest number of patents in nanomedicine followed by, rare diseases. For nanomedicine, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Coherus BioSciences portfolio followed by choriocarcinoma (gestational trophoblastic neoplasia), and small-cell lung cancer
Coherus BioSciences has highest number of patents in breast cancer followed by choriocarcinoma (gestational trophoblastic neoplasia), small-cell lung cancer, non-small cell lung carcinoma, and laryngeal cancer.
For comprehensive analysis of Coherus BioSciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.